Roche continues to invest significantly in research of HIV. Group at Roche Discovery Welwyn, United Kingdom, offers programs in the areas of new protease inhibitors, non-nucleoside inhibitors of reverse transcriptase, as well as chemokines receptor inhibitors (agents that associate with specific sites on the CD4 cell and prevent a virus). In addition, Roche has developed Valganciclovir, a drug that will optimize the treatment of CMV infection when obtaining blood levels of drug orally similar to those obtained by intravenous route.
Roche continued investment in molecular diagnostics will allow the rapid detection and analysis of the HIV virus resistant to mediation, taking into account the treatment is optimized and best use of available resources for people living with HIV / AIDS. Roche is supporting several initiatives (Solutions for Integrated Health Care) in the area of HIV resistance to antiviral drugs that will optimize treatment and improve the use of resources for people receiving treatment for high efficiency. Roche is actively engaged to participate in programs initiated by WHO, UNAIDS and other international organizations to provide access to HIV treatment in developing countries
Roche has been investigated in this highly effective drug development:
* Enfuvirtide – Fuzeon ™: First fusion inhibitor of HIV.
*
Ganciclovir – Cymevene ™: guanine analogue that inhibits the replication of viruses such as cytomegalovirus and herpes virus.
*
Saquinavir – Fortovase ™: selective inhibitors of HIV protease proteinase.
*
Saquinavir sgc – Fortovase ™: protease inhibitor in a new formulation (soft gelatin capsule).
*
Valganciclovir – Valixa ™: VALIXA is indicated for the treatment of induction and maintenance of cytomegalovirus retinitis (CMV retinitis) in patients with acquired immunodeficiency syndrome (AIDS).
VALIXA is also indicated for the prevention of CMV disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor.
*
Zalcitabine – Hivid ™: Combination therapy with zidovudine (AZT) in patients with advanced HIV.